During his time at Ligand Pharmaceuticals, John L. Higgins had substantial stakes in the company, especially during his peak years. His wealth has seen significant fluctuations; for instance, in 2018, he held over $3.5 million in vested stock, reflecting his...

During his time at Ligand Pharmaceuticals, John L. Higgins had substantial stakes in the company, especially during his peak years. His wealth has seen significant fluctuations; for instance, in 2018, he held over $3.5 million in vested stock, reflecting his success with performance-based equity. Post-2018, however, his stock holdings decreased with his anticipated retirement, indicating a shift in assets. By 2022, he did not report any vested stocks, aligning with his exit strategy. His stock stakes generally showed a trend of being closely tied to Ligand's performance metrics, revealing both his commitment and the risks involved in high-stakes biotech leadership. This strategic approach towards stock holding reflects a desire for aligning his wealth accumulation with the company’s growth trajectory.